IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Solid Tumors

About this trial
This is an interventional treatment trial for Solid Tumors
Eligibility Criteria
Inclusion Criteria: Male or female subjects ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; Anticipated life expectancy of ≥ 12 weeks; Adequate bone marrow and organ function; Criteria for dose escalation phase only: Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available (mainly focused on non-small-cell lung cancer, head and neck squamous cell carcinoma and RAS-wildtype colorectal cancer); At least 1 evaluable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Criteria for dose expansion phase only: Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma or RAS-wildtype colorectal cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria: Participate in any other interventional clinical research except observational (non-interventional) study or in the follow-up phase of the interventional study; Received live vaccines within 4 weeks prior to first dose of the study drug or plan on receiving any live vaccine during the study; Received total pelvic radiotherapy; Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours); Uncontrolled diseases; History of endotracheal or gastrointestinal stent implantation; Multiple concurrent malignant tumors within 5 years (except non-melanoma skin cancer, carcinoma in situ or non-invasive tumor that were cured); Women who are pregnant, have positive results in pregnancy test or are lactating; Not eligible to participate in this study at the discretion of the investigator.
Sites / Locations
- Westmead HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
IBI334 E
IBI334 D
IBI334 C
IBI334 A
IBI334 F
IBI334 B